Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2020 - 2026)

Monte Rosa Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 19.96% year-over-year to $71.0 million; the TTM figure through Mar 2026 stood at $71.0 million (up 19.96% YoY), while the FY2025 annual figure was $64.2 million, down 59.09% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $71.0 million, up from $64.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $156.9 million in Q4 2024, with the low at $12.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $41.6 million (2024), against an average of $44.9 million.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 236.85% in 2024, then plunged 59.09% in 2025.
• Monte Rosa Therapeutics' Total Current Liabilities stood at $25.6 million in 2022, then surged by 82.22% to $46.6 million in 2023, then soared by 236.85% to $156.9 million in 2024, then slumped by 59.09% to $64.2 million in 2025, then gained by 10.63% to $71.0 million in 2026.
• Business Quant data shows GLUE's Total Current Liabilities at $71.0 million in Q1 2026, $64.2 million in Q4 2025, and $61.4 million in Q3 2025.